MELBOURNE, Australia, November 14, 2011 /PRNewswire/ --
ImmunAid Pty. Ltd. has been awarded a European patent for its pioneering work in the treatment of cancer, based on monitoring the immune cycle of each individual patient and then determining the optimal time to deliver treatment to that patient.
Dr. Svetomir Markovic, chair of the Melanoma Group at Mayo Clinic, Rochester, MN, has said, "The discovery of the regulated immune response cycle in cancer patients is potentially of immense clinical significance with profound public health implications."
Approximately 23 billion Euros is spent globally each year on cancer drugs, yet the cancer mortality rate in the European Union this year will be app. 1.3 Mill. people, worldwide it is about 7.6 Mill. with the mortality rate essentially unchanged over the last 50 years. An analysis of 63 major clinical trials published since 2000 shows the average complete response rate--becoming cancer free--in late-stage patients across a wide range of cancers is approximately 7 percent. The discoveries by ImmunAid may now explain this historical success rate. The possibility now exists to significantly improve such survival rates by applying the ImmunAid invention of time treatment.
ImmunAid Pty. Ltd. is a private Australian biotechnology company, majority owned by Genetic Technologies Limited (ASX-GTG, NASDAQ-GENE). ImmunAid was founded a decade ago to explore the concept developed by inventor Martin Ashdown that the immune system switches itself "on and off" in a continuous, repeating cycle in patients with certain diseases such as chronic infections including HIV, and that treatment should be timed to support the body's own efforts to fight off such disease. Subsequently, Ashdown expanded his concept to include cancer, autoimmune and several degenerative diseases.
Ashdown and the ImmunAid research team demonstrated that the immune system of cancer patients undergoes a repeating cycle, and that the administration of treatment at certain critical moments within that cycle can significantly improve the clinical outcome.
Dr. Mervyn Jacobson, ImmunAid chief executive officer, says. "Once we realized this immune cycle is real and measurable, we postulated that the timing of the administration of chemotherapy and other anti-cancer therapies would affect the outcomes and should be personally timed to work with each individual patient's immune system to attack the cancer. The results then spoke for themselves."
Professor Brendon Coventry, a senior surgical consultant and practicing surgeon at Royal Adelaide Hospital, has conducted clinical trials over several years in conjunction with ImmunAid. He says, "Treatments 'randomly' given without consideration to a patient's immune cycle explains why some patients achieve a complete recovery and others do not."
The Mayo Clinic currently is conducting a clinical trial to further assess the influence of timed delivery of conventional chemotherapy for patients with cancer, and several hospitals and universities in Australia are now conducting trials on cancer. These follow from investigations in a number of other diseases, including multiple sclerosis and human immunodeficiency virus (HIV).
Dr. Markovic stated, "I have been struck by the scientific community's acknowledgement of the increasing validity of ImmunAid's work. In Mayo's ongoing experience, timed delivery of chemotherapy appears to offer added therapeutic benefit in the treatment of metastatic melanoma."
ImmunAid Pty. Ltd.
Dr. Andrea Tobisch
SOURCE ImmunAid Pty. Ltd.